Lymphoma
Showing NaN - NaN of 168
Lymphoma, Multiple Myeloma Trial in Worldwide (Lenalidomide, Dexamethasone, Dexamethasone (Oral))
Completed
- Lymphoma
- Multiple Myeloma
- Lenalidomide
- +4 more
-
Muscle Shoals, Alabama
- +215 more
May 5, 2022
Gastrointestinal Cancer, Lymphoma, Thoracic Cancer Trial in Boston, Brighton, Methuen (SURGE, Standard of Care)
Not yet recruiting
- Gastrointestinal Cancer
- +2 more
- SURGE
- Standard of Care
-
Boston, Massachusetts
- +2 more
May 11, 2022
Lymphoma, Survivorship Trial in Boston (Interview with Clinicians, Field Test of UPLYFT with Lymphoma Survivors, Pilot of UPLYFT
Recruiting
- Lymphoma
- Survivorship
- Interview with Clinicians
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Mar 14, 2022
Lymphoma Trial in United States (rituximab, Bendamustin, bortezomib)
Active, not recruiting
- Lymphoma
- rituximab
- +3 more
-
Greenbrae, California
- +226 more
Mar 7, 2022
Lymphoma, Autonomic Imbalance, Cancer Survivorship Trial in Boston (Ivabradine, Placebo Oral Tablet)
Terminated
- Lymphoma
- +2 more
- Ivabradine
- Placebo Oral Tablet
-
Boston, Massachusetts
- +2 more
Jan 19, 2022
Breast Cancer, Lymphoma Trial in United States (Atorvastatin, Placebo)
Lymphoma Trial in Boston (3RP-Lymphoma)
Completed
- Lymphoma
- 3RP-Lymphoma
-
Boston, MassachusettsMassachusetts General Hospital
Nov 9, 2021
Hematologic Malignancy, Leukemia, Lymphoma Trial in Boston (CAR-37 T cells)
Recruiting
- Hematologic Malignancy
- +5 more
- CAR-37 T cells
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Oct 28, 2021
Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplasia Trial in United States (Mobilized Peripheral Blood Stem Cell
Active, not recruiting
- Acute Leukemia
- +3 more
- Mobilized Peripheral Blood Stem Cell graft with Tacrolimus/Methotrexate
- +5 more
-
Birmingham, Alabama
- +38 more
Oct 25, 2021
Solid Tumor, Adult Trial in United States (LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER,
Recruiting
- Solid Tumor, Adult
- Lymphoma
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER
- Pembrolizumab - anti-PD-1 antibody
-
Los Angeles, California
- +7 more
Oct 11, 2021
Lymphoma Trial in Boston (Home Hospital for Lymphoma)
Withdrawn
- Lymphoma
- Home Hospital for Lymphoma
-
Boston, MassachusettsMassachusetts General Hospital Cancer Center
Aug 31, 2021
Leukemia, Lymphoma Trial in United States (biological, drug, procedure)
Active, not recruiting
- Leukemia
- Lymphoma
- rituximab
- +7 more
-
Duarte, California
- +24 more
Aug 16, 2021
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML) Trial in Worldwide (NiCord®
Active, not recruiting
- Hematological Malignancies
- +6 more
- NiCord® (omidubicel)
- Cord Blood Unit
-
Los Angeles, California
- +51 more
Jan 7, 2021
Breast Carcinoma, Cancer Survivor, Depression Trial in United States (procedure, other, behavioral)
Completed
- Breast Carcinoma
- +12 more
- Management of Therapy Complications
- +3 more
-
Los Angeles, California
- +5 more
Oct 8, 2020